{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T07:44:56Z","timestamp":1648971896154},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1001\/jamadermatol.2018.5951","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T15:57:41Z","timestamp":1555516661000},"page":"754","source":"Crossref","is-referenced-by-count":2,"title":["Learning About Dupilumab-Associated Conjunctivitis"],"prefix":"10.1001","volume":"155","author":[{"given":"Aleksi J.","family":"Hendricks","sequence":"first","affiliation":[{"name":"University of Arizona College of Medicine, Tucson"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[{"name":"University of Arizona Department of Medicine, Division of Dermatology, Tucson"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"10","key":"dle180023r1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis.","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"10086","key":"dle180023r2","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"dle180023r3","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"26","key":"dle180023r4","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma.","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"dle180023r5","first-page":"25","article-title":"Case report: first reported case of facial rash after dupilumab therapy.","volume":"April","author":"Dalia","year":"2018","journal-title":"Pract Dermatol"},{"issue":"6","key":"dle180023r6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/eye.2016.298","article-title":"Hydroxychloroquine retinopathy.","volume":"31","author":"Yusuf","year":"2017","journal-title":"Eye (Lond)"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamadermatology\/article-pdf\/155\/6\/754\/17657608\/jamadermatology_hendricks_2019_le_180023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T11:22:30Z","timestamp":1560338550000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.5951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.5951","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}